Report : Middle East & Africa Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology (Molecular Diagnostics {Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, Microarrays}, Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology), Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)

At 8.2% CAGR, the Middle East & Africa Sepsis Diagnostics Market is speculated to be worth US$ 33.35 million by 2028, says Business Market Insights           

According to Business Market Insights’ research, the MEA sepsis diagnostics market was valued at US$ 19.20 million in 2021 and is expected to reach US$ 33.35 million by 2028, registering an annual growth rate of 8.2% from 2021 to 2028. Large incidence of sepsis due to increasing nosocomial infections and high in demand for rapid diagnostic tests leading to increasing product launches are the critical factors attributed to the market expansion.               

Sepsis diagnosis requires laboratory skills and proficiency to process the collection and investigation of the clinical sample. Sepsis is a life-threatening illness that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The lack of experienced professionals is a significant concern MEA. For instance, according to an article published in Young Scientist Journal (YSJ) in April 2018, Sub-Saharan Africa faced a critical shortage of healthcare workers. The deficit is due to the declining emigration of healthcare professionals and the lack of proper healthcare infrastructure and medical graduates, which acts as a restraint on the development of the public health system in that region. Sub-Saharan Africa is considered to have the weakest healthcare system globally. Such restrictions are expected to hamper the growth of the global sepsis diagnostics market over the forecast period. Additionally, only 50% of patients, with severe sepsis, transported by the emergency medical software (EMS) system, have a paramedic. The lack of trained paramedics affects each phase of patient care in sepsis awareness and screening of patients for the presence of sepsis. This is expected to drive the market during the forecast period.

On the contrary, shortage of skilled professionals hurdles the growth of MEA sepsis diagnostics market. 

Based on product, the MEA sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.5% market share in 2021, amassing US$ 8.35 million. It is projected to garner US$ 14.39 million by 2028 to expand at 8.1% CAGR during 2021–2028.    

Based on technology, the MEA sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.4% market share in 2021, amassing US$ 8.53 million. It is projected to garner US$ 14.57 million by 2028 to expand at 7.9% CAGR during 2021–2028. Further molecular diagnostics flow cytometry segment is further categorized into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, microarrays.

Based on Method, the MEA sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.4% market share in 2021, amassing US$ 12.76 million. It is projected to garner US$ 21.90 million by 2028 to expand at 8.0% CAGR during 2021–2028 

Based on test type, the MEA sepsis diagnostics market is divided into point-of-care tests and laboratory tests. The laboratory tests segment held 84.8% market share in 2021, amassing US$ 16.28 million. It is projected to garner US$ 28.16 million by 2028 to expand at 8.1% CAGR during 2021–2028 

Based on pathogen, the MEA sepsis diagnostics market is divided into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.7% market share in 2021, amassing US$ 15.31 million. It is projected to garner US$ 26.98 million by 2028 to expand at 8.4% CAGR during 2021–2028 

Based on end user, the MEA sepsis diagnostics market is divided into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.9% market share in 2021, amassing US$ 9.19 million. It is projected to garner US$ 16.09 million by 2028 to expand at 8.3% CAGR during 2021–2028 

Based on country, the MEA sepsis diagnostics market has been categorised into the Saudi Arabia, South Africa, UAE, and Rest of MEA.  Our regional analysis states that Saudi Arabia captured 29.2% market share in 2021. It was assessed at US$ 5.61 million in 2021 and is likely to hit US$ 9.82 million by 2028, exhibiting a CAGR of 8.3% during the forecast period.            

Key players dominating the MEA sepsis diagnostics market are Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. among others.

  • In July 2018, Thermo Scientific BRAHMS PCT direct blood test allows fast bacterial infection and sepsis diagnosis.
  • In Mar 2019, Beckman Coulter launches new immunoassay system for sepsis.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

Download Free PDF Brochure